Gallic acid prevents isoproterenol-induced cardiac hypertrophy and fibrosis through regulation of JNK2 signaling and Smad3 binding activity

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Ryu, Yuhee ^a   Jin, Li ^a,b   Kee, Hae Jin ^a   Piao, Zhe Hao ^b   Cho, Jae Yeong ^a   Kim, Gwi Ran ^a   Choi, Sin Young ^a   Lin, Ming Quan ^a,c   Jeong, Myung Ho ^a  

^a Chonnam National University Medical School   (South Korea)

^b JILIN UNIVERSITY   (China)

^c YANBIAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GALLIC ACID; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE 9; PROTEIN BINDING; SMAD3 PROTEIN; SMAD3 PROTEIN, MOUSE;

ANIMAL; CARDIOMEGALY; CELL CULTURE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECT; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; MALE; METABOLISM; MOUSE; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMEGALY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FIBROSIS; GALLIC ACID; GENE EXPRESSION REGULATION; HEART VENTRICLES; ISOPROTERENOL; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 9; PROTEIN BINDING; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; VENTRICULAR FUNCTION, LEFT;

EID: 84990035808     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep34790     Document Type: Article

References (48)

1. Jeong, M. Y., Kinugawa, K., Vinson, C., Long, C. S. AFos dissociates cardiac myocyte hypertrophy and expression of the pathological gene program. Circulation 111, 1645-1651 (2005).
2. Kang, Y. J. Cardiac hypertrophy: a risk factor for QT-prolongation and cardiac sudden death. Toxicol Pathol 34, 58-66 (2006).
3. Creemers, E. E., Pinto, Y. M. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 89, 265-272 (2011).
4. Fan, D., Takawale, A., Lee, J., Kassiri, Z. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair 5, 15 (2012).
5. McKinsey, T. A., Olson, E. N. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest 115, 538-546 (2005).
6. Zhai, Y., Gao, X., Wu, Q., Peng, L., Lin, J. et al. Fluvastatin decreases cardiac fibrosis possibly through regulation of TGF-beta(1)/Smad 7 expression in the spontaneously hypertensive rats. Eur J Pharmacol 587, 196-203 (2008).
7. Inagaki, K., Koyanagi, T., Berry, N. C., Sun, L., Mochly-Rosen, D. Pharmacological inhibition of epsilon-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure. Hypertension 51, 1565-1569 (2008).
8. Izawa, H., Murohara, T., Nagata, K., Isobe, S., Asano, H. et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 112, 2940-2945 (2005).
9. Ciulla, M. M., Paliotti, R., Esposito, A., Diez, J., Lopez, B. et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation 110, 552-557 (2004).
10. Meng, X. M., Huang, X. R., Chung, A. C., Qin, W., Shao, X. et al. Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J Am Soc Nephrol 21, 1477-1487 (2010).
11. Qin, W., Chung, A. C., Huang, X. R., Meng, X. M., Hui, D. S. et al. TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol 22, 1462-1474 (2011).
12. Huang, X. R., Chung, A. C., Yang, F., Yue, W., Deng, C. et al. Smad3 mediates cardiac inflammation and fibrosis in angiotensin IIinduced hypertensive cardiac remodeling. Hypertension 55, 1165-1171 (2010).
13. Biernacka, A., Cavalera, M., Wang, J., Russo, I., Shinde, A. et al. Smad3 Signaling Promotes Fibrosis While Preserving Cardiac and Aortic Geometry in Obese Diabetic Mice. Circ Heart Fail 8, 788-798 (2015).
14. Murata, M., Yoshida, K., Yamaguchi, T., Matsuzaki, K. Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma. World J Gastroenterol 20, 15018-15027 (2014).
15. Furukawa, F., Matsuzaki, K., Mori, S., Tahashi, Y., Yoshida, K. et al. p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 38, 879-889 (2003).
16. Browne, J. A., Liu, X., Schnaper, H. W., Hayashida, T. Serine-204 in the linker region of Smad3 mediates the collagen-I response to TGF-beta in a cell phenotype-specific manner. Exp Cell Res 319, 2928-2937 (2013).
17. Yan, L., Zhang, J. D., Wang, B., Lv, Y. J., Jiang, H. et al. Quercetin inhibits left ventricular hypertrophy in spontaneously hypertensive rats and inhibits angiotensin II-induced H9C2 cells hypertrophy by enhancing PPAR-gamma expression and suppressing AP-1 activity. PLoS One 8, e72548 (2013).
18. Dolinsky, V. W., Soltys, C. L., Rogan, K. J., Chan, A. Y., Nagendran, J. et al. Resveratrol prevents pathological but not physiological cardiac hypertrophy. J Mol Med (Berl) 93, 413-425 (2015).
19. Morimoto, T., Sunagawa, Y., Kawamura, T., Takaya, T., Wada, H. et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest 118, 868-878 (2008).
20. Dolinsky, V. W., Chan, A. Y., Robillard Frayne, I., Light, P. E., Des Rosiers, C. et al. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 119, 1643-1652 (2009).
21. Kee, H. J., Kim, G. R., Kim, I. K., Jeong, M. H. Sulforaphane suppresses cardiac hypertrophy by inhibiting GATA4/GATA6 expression and MAPK signaling pathways. Mol Nutr Food Res 59, 221-230 (2015).
22. Kee, H. J., Park, S., Kang, W., Lim, K. S., Kim, J. H. et al. Piceatannol attenuates cardiac hypertrophy in an animal model through regulation of the expression and binding of the transcription factor GATA binding factor 6. FEBS Lett 588, 1529-1536 (2014).
23. Choubey, S., Varughese, L. R., Kumar, V., Beniwal, V. Medicinal importance of gallic acid and its ester derivatives: a patent review. Pharm Pat Anal 4, 305-315 (2015).
24. Patel, S. S., Goyal, R. K. Cardioprotective effects of gallic acid in diabetes-induced myocardial dysfunction in rats. Pharmacognosy Res 3, 239-245 (2011).
25. Kim, S. H., Jun, C. D., Suk, K., Choi, B. J., Lim, H. et al. Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells. Toxicol Sci 91, 123-131 (2006).
26. Nair, G. G., Nair, C. K. Radioprotective effects of gallic acid in mice. Biomed Res Int 2013, 953079 (2013).
27. Kee, H. J., Cho, S. N., Kim, G. R., Choi, S. Y., Ryu, Y. et al. Gallic acid inhibits vascular calcification through the blockade of BMP2-Smad1/5/8 signaling pathway. Vascul Pharmacol 63, 71-78 (2014).
28. Doan, K. V., Ko, C. M., Kinyua, A. W., Yang, D. J., Choi, Y. H. et al. Gallic acid regulates body weight and glucose homeostasis through AMPK activation. Endocrinology 156, 157-168 (2015).
29. Sahn, D. J., DeMaria, A., Kisslo, J., Weyman, A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58, 1072-1083 (1978).
30. Choi, S. Y., Ryu, Y., Kee, H. J., Cho, S. N., Kim, G. R. et al. Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes. Vascul Pharmacol 72, 130-140 (2015).
31. Kee, H. J., Kook, H. Kruppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy. J Mol Cell Cardiol 47, 770-780 (2009).
32. Kee, H. J., Kim, J. R., Nam, K. I., Park, H. Y., Shin, S. et al. Enhancer of polycomb1, a novel homeodomain only protein-binding partner, induces skeletal muscle differentiation. J Biol Chem 282, 7700-7709 (2007).
33. Chao, J., Huo, T. I., Cheng, H. Y., Tsai, J. C., Liao, J. W. et al. Gallic acid ameliorated impaired glucose and lipid homeostasis in high fat diet-induced NAFLD mice. PLoS One 9, e96969 (2014).
34. Niho, N., Shibutani, M., Tamura, T., Toyoda, K., Uneyama, C. et al. Subchronic toxicity study of gallic acid by oral administration in F344 rats. Food Chem Toxicol 39, 1063-1070 (2001).
35. Akazawa, H., Komuro, I. Roles of cardiac transcription factors in cardiac hypertrophy. Circ Res 92, 1079-1088 (2003).
36. Zhang, W., Elimban, V., Nijjar, M. S., Gupta, S. K., Dhalla, N. S. Role of mitogen-activated protein kinase in cardiac hypertrophy and heart failure. Exp Clin Cardiol 8, 173-183 (2003).
37. Sato, M., Muragaki, Y., Saika, S., Roberts, A. B., Ooshima, A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 112, 1486-1494 (2003).
38. Kohli, S., Ahuja, S., Rani, V. Transcription factors in heart: promising therapeutic targets in cardiac hypertrophy. Curr Cardiol Rev 7, 262-271 (2011).
39. Kehat, I., Molkentin, J. D. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 122, 2727-2735 (2010).
40. Hsu, S., Nagayama, T., Koitabashi, N., Zhang, M., Zhou, L. et al. Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. Cardiovasc Res 81, 301-309 (2009).
41. Du, X. J. Divergence of hypertrophic growth and fetal gene profile: the influence of beta-blockers. Br J Pharmacol 152, 169-171 (2007).
42. Rose, B. A., Force, T., Wang, Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev 90, 1507-1546 (2010).
43. Wang, Y., Su, B., Sah, V. P., Brown, J. H., Han, J. et al. Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J Biol Chem 273, 5423-5426 (1998).
44. Zou, Y., Yao, A., Zhu, W., Kudoh, S., Hiroi, Y. et al. Isoproterenol activates extracellular signal-regulated protein kinases in cardiomyocytes through calcineurin. Circulation 104, 102-108 (2001).
45. Tachibana, H., Perrino, C., Takaoka, H., Davis, R. J., Naga Prasad, S. V. et al. JNK1 is required to preserve cardiac function in the early response to pressure overload. Biochem Biophys Res Commun 343, 1060-1066 (2006).
46. Izumiya, Y., Kim, S., Izumi, Y., Yoshida, K., Yoshiyama, M. et al. Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling. Circ Res 93, 874-883 (2003).
47. Kluwe, J., Pradere, J. P., Gwak, G. Y., Mencin, A., De Minicis, S. et al. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 138, 347-359 (2010).
48. Banerjee, I., Fuseler, J. W., Price, R. L., Borg, T. K., Baudino, T. A. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am J Physiol Heart Circ Physiol 293, H1883-H1891 (2007).